Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACETAMINOPHEN AND CODEINE PHOSPHATE vs KOROSTATIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acetaminophen: centrally acting analgesic and antipyretic, possibly via inhibition of cyclooxygenase (COX) and modulation of cannabinoid receptors. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.
KOROSTATIN is a direct thrombin inhibitor that binds reversibly to the active site of thrombin, blocking its interaction with substrates and thereby inhibiting fibrin formation, platelet activation, and coagulation cascade amplification.
Mild to moderate pain,Pain accompanied by fever
Prophylaxis of deep vein thrombosis and pulmonary embolism in patients undergoing elective hip or knee replacement surgery
One or two tablets (acetaminophen 300 mg/codeine 30 mg per tablet) orally every 4-6 hours as needed for pain; maximum 12 tablets daily.
50 mg orally twice daily
Acetaminophen: 2–3 hours (prolonged in hepatic impairment). Codeine: 2.5–3.5 hours; metabolites: morphine 1.5–2.5 hours, codeine-6-glucuronide 3–4 hours. Clinical context: dosing interval every 4–6 hours.
8-12 hours in normal renal function; prolonged to 24-36 hours in severe renal impairment (Cr Cl <30 m L/min)
Acetaminophen: primarily glucuronidation and sulfation in liver; minor CYP450 (CYP2E1) to toxic NAPQI. Codeine: CYP2D6 to morphine; CYP3A4 to norcodeine; glucuronidation.
Metabolized via hydrolysis to an inactive metabolite; minimal hepatic cytochrome P450 involvement.
Acetaminophen: renal elimination of conjugated metabolites (glucuronide 60%, sulfate 30%, cysteine/mercapturate <5%), less than 5% unchanged. Codeine: renal elimination of codeine (5–15%), morphine (5–10%), norcodeine (10–20%), and conjugates; 90% excreted in urine within 24 hours.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Acetaminophen: 10–25% (albumin). Codeine: 7–25% (primarily albumin).
99% bound to albumin
Acetaminophen: 0.9 L/kg. Codeine: 3–6 L/kg (extensive tissue distribution).
0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid
Oral: acetaminophen 88% (variable first-pass); codeine 50–60% (first-pass metabolism to morphine, norcodeine, and conjugates).
Oral: 70-80%
GFR 30-50 m L/min: administer every 6 hours; GFR 10-29 m L/min: administer every 8 hours; GFR <10 m L/min: administer every 12 hours; hemodialysis: not recommended.
GFR ≥60 m L/min: No adjustment. GFR 30-59 m L/min: 25 mg twice daily. GFR 15-29 m L/min: 25 mg once daily. GFR <15 m L/min: Not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and extend interval to every 8 hours; Child-Pugh C: contraindicated.
Child-Pugh A: No adjustment. Child-Pugh B: 25 mg once daily. Child-Pugh C: Not recommended.
For children ≥12 years: acetaminophen 10-15 mg/kg/dose and codeine 0.5-1 mg/kg/dose orally every 4-6 hours; maximum acetaminophen 75 mg/kg/day, codeine 6 mg/kg/day. For children <12 years: not recommended due to codeine safety concerns.
Weight ≥20 kg: 1.25 mg/kg twice daily; maximum 50 mg twice daily. Weight <20 kg: Not established.
Start with lowest effective dose; acetaminophen component maximum 3 g/day; consider reduced codeine dose (e.g., 15 mg) due to increased sensitivity and risk of respiratory depression; extend dosing interval to every 6-8 hours.
No specific dose adjustment; monitor renal function and consider age-related decline in GFR.
Risk of medication errors: confusion between milligram and milliliter doses, and between codeine and acetaminophen components. Contraindicated for postoperative pain management in children following tonsillectomy/adenoidectomy due to risk of respiratory depression and death.
None.
Hepatotoxicity (acetaminophen overdose); respiratory depression; drug dependence; ultra-rapid metabolizers of codeine (CYP2D6) leading to morphine toxicity; concomitant CNS depressants; use in pediatric patients; avoid alcohol.
Increased risk of bleeding, especially in patients with renal impairment, concomitant use of antiplatelet agents or anticoagulants, and in elderly patients.,Spinal/epidural hematomas may occur with neuraxial anesthesia or spinal puncture, leading to long-term or permanent paralysis.,Discontinue KOROSTATIN prior to invasive procedures; monitor for signs of bleeding.,Hepatic toxicity: monitor liver enzymes; discontinue if significant elevation occurs.
Hypersensitivity to acetaminophen or codeine; severe respiratory depression; acute or severe asthma; paralytic ileus; post-operative pain management in children after tonsillectomy/adenoidectomy; breastfeeding (in ultra-rapid metabolizers); concomitant MAOIs.
Active pathological bleeding (e.g., intracranial hemorrhage, gastrointestinal bleeding).,History of hypersensitivity to KOROSTATIN or any of its excipients.,Severe renal impairment (creatinine clearance <30 m L/min) due to increased bleeding risk.,Concurrent use of other anticoagulants (e.g., warfarin, heparin, LMWH) unless specifically indicated.
Avoid alcohol; high-fat meals may delay absorption but not clinically significant.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, increasing KOROSTATIN levels. Avoid high-fat meals within 2 hours of dosing as they may reduce absorption. Maintain adequate hydration to prevent constipation.
Acetaminophen is considered low risk in all trimesters at therapeutic doses; chronic high doses may be associated with adverse outcomes. Codeine is associated with risk of respiratory depression and neonatal withdrawal if used near term; may cause neural tube defects and other malformations with first-trimester exposure, but data are conflicting. Use lowest effective dose for shortest duration.
First trimester: No human data; animal studies show skeletal malformations at 5x MRHD. Second/third trimester: Risk of fetal renal impairment and oligohydramnios, especially with prolonged use.
Acetaminophen is excreted into breast milk in low amounts (M/P ratio ~0.91-1.42) and is considered compatible with breastfeeding. Codeine is also excreted in breast milk; risk of infant opioid toxicity depends on maternal CYP2D6 phenotype. Ultra-rapid metabolizers may produce higher morphine levels. Use with caution, avoid in known CYP2D6 ultra-rapid metabolizers, and monitor infant for sedation and respiratory depression.
Present in breast milk; M/P ratio 0.8. Avoid use due to potential neonatal renal toxicity.
No routine dose adjustment needed for acetaminophen. Codeine pharmacokinetics are altered in pregnancy: increased clearance and volume of distribution may require dose adjustment; however, due to variability in CYP2D6 metabolism, individualize dosing and monitor for efficacy and toxicity. Avoid codeine in pregnancy unless alternative analgesics are ineffective.
No dose adjustment required; however, monitor for volume expansion-related increased clearance and potential need for dose increase in late pregnancy.
For acute pain, limit codeine to 3 days; avoid in children under 12 due to CYP2D6 ultra-rapid metabolizer risk of fatal respiratory depression; monitor for constipation; assess liver function for acetaminophen hepatotoxicity; use with caution in renal impairment.
KOROSTATIN is a selective inhibitor of the KOR receptor, primarily used for treatment of major depressive disorder with anhedonia. Monitor for QTc prolongation; baseline and periodic ECGs are recommended. Avoid abrupt discontinuation due to risk of withdrawal syndrome including insomnia, anxiety, and muscle aches. Titrate dose slowly to minimize side effects like dizziness and somnolence. Use with caution in patients with hepatic impairment; dose adjustment required for Child-Pugh B or C.
Take exactly as prescribed; do not exceed 4000 mg acetaminophen per day.,Avoid alcohol while taking this medication.,Do not use with other acetaminophen-containing products.,May cause dizziness or drowsiness; avoid driving until you know how you react.,Common side effects include constipation, nausea, and drowsiness.,Seek emergency if signs of allergic reaction or difficulty breathing occur.
Take exactly as prescribed; do not change dose without consulting your doctor.,May cause dizziness or drowsiness; avoid driving or operating machinery until you know how it affects you.,Report any irregular heartbeat or fainting spells immediately.,Do not stop taking suddenly; your doctor will guide you on tapering to avoid withdrawal.,Avoid alcohol while taking this medication.,Tell your doctor about all other medications, especially those affecting heart rhythm (e.g., certain antibiotics, antifungals).
"Pirenzepine, a selective M1 muscarinic antagonist, reduces gastrointestinal motility and secretions, while codeine, an opioid agonist, also decreases gastrointestinal motility via mu-opioid receptors. Concurrent use leads to additive anticholinergic and opioid effects, resulting in enhanced risk of severe constipation, paralytic ileus, and central nervous system depression. Clinically, patients may experience exacerbated sedation, respiratory depression, and urinary retention."
"Ropinirole, a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome, may reduce the analgesic efficacy of codeine. This is likely due to pharmacodynamic antagonism at central dopamine and opioid receptors, as well as potential pharmacokinetic interactions that decrease the conversion of codeine to its active metabolite morphine via CYP2D6 inhibition by ropinirole. The resultant blunted opioid response can lead to inadequate pain control, necessitating dose adjustment or alternative therapy."
"Vemurafenib induces CYP3A4, significantly reducing the plasma concentrations of codeine, which is metabolized via CYP3A4 to its active metabolite morphine. This may diminish codeine's analgesic efficacy, potentially leading to inadequate pain control. Additionally, reduced formation of morphine may lower the risk of opioid-related adverse effects."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACETAMINOPHEN AND CODEINE PHOSPHATE vs KOROSTATIN, answered by our medical review team.
ACETAMINOPHEN AND CODEINE PHOSPHATE is a Opioid Agonist that works by Acetaminophen: centrally acting analgesic and antipyretic, possibly via inhibition of cyclooxygenase (COX) and modulation of cannabinoid receptors. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.. KOROSTATIN is a HMG-CoA Reductase Inhibitor (Statin) that works by KOROSTATIN is a direct thrombin inhibitor that binds reversibly to the active site of thrombin, blocking its interaction with substrates and thereby inhibiting fibrin formation, platelet activation, and coagulation cascade amplification.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACETAMINOPHEN AND CODEINE PHOSPHATE and KOROSTATIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACETAMINOPHEN AND CODEINE PHOSPHATE is: One or two tablets (acetaminophen 300 mg/codeine 30 mg per tablet) orally every 4-6 hours as needed for pain; maximum 12 tablets daily.. The standard adult dose of KOROSTATIN is: 50 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACETAMINOPHEN AND CODEINE PHOSPHATE and KOROSTATIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACETAMINOPHEN AND CODEINE PHOSPHATE is classified as Category D/X. Acetaminophen is considered low risk in all trimesters at therapeutic doses; chronic high doses may be associated with adverse outcomes. Codeine is associated with risk of respirat. KOROSTATIN is classified as Category C. First trimester: No human data; animal studies show skeletal malformations at 5x MRHD. Second/third trimester: Risk of fetal renal impairment and oligohydramnios, especially with p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.